Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability.

Lee DW, Zhong S, Pai R, Rae J, Sukumaran S, Stefanich EG, Lutman J, Doudement E, Wang X, Harder B, Lekkerkerker A, Herman A, Ouyang W, Danilenko DM.

Pharmacol Res Perspect. 2018 Nov 15;6(6):e00434. doi: 10.1002/prp2.434. eCollection 2018 Dec.


Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury.

Rothenberg ME, Wang Y, Lekkerkerker A, Danilenko DM, Maciuca R, Erickson R, Herman A, Stefanich E, Lu TT.

Clin Pharmacol Ther. 2018 Jun 28. doi: 10.1002/cpt.1164. [Epub ahead of print]


Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases.

Stefanich EG, Rae J, Sukumaran S, Lutman J, Lekkerkerker A, Ouyang W, Wang X, Lee D, Danilenko DM, Diehl L, Loyet KM, Herman A.

Biochem Pharmacol. 2018 Jun;152:224-235. doi: 10.1016/j.bcp.2018.03.031. Epub 2018 Mar 31.


Antibacterial Defense of Human Airway Epithelial Cells from Chronic Obstructive Pulmonary Disease Patients Induced by Acute Exposure to Nontypeable Haemophilus influenzae: Modulation by Cigarette Smoke.

Amatngalim GD, Schrumpf JA, Henic A, Dronkers E, Verhoosel RM, Ordonez SR, Haagsman HP, Fuentes ME, Sridhar S, Aarbiou J, Janssen RAJ, Lekkerkerker AN, Hiemstra PS.

J Innate Immun. 2017;9(4):359-374. doi: 10.1159/000455193. Epub 2017 Feb 8.


Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein RNase 7.

Amatngalim GD, van Wijck Y, de Mooij-Eijk Y, Verhoosel RM, Harder J, Lekkerkerker AN, Janssen RA, Hiemstra PS.

J Immunol. 2015 Apr 1;194(7):3340-50. doi: 10.4049/jimmunol.1402169. Epub 2015 Feb 23.


SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.


Cellular players in lung fibrosis.

Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA.

Curr Pharm Des. 2012;18(27):4093-102. Review.


Viral piracy: HIV-1 targets dendritic cells for transmission.

Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB.

Curr HIV Res. 2006 Apr;4(2):169-76. Review.


Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.

Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB.

Virology. 2004 Nov 24;329(2):465-76.


Mucosal-targeted AIDS vaccines: the next generation?

Lekkerkerker AN, Van Kooyk Y, Geijtenbeek TB.

Trends Microbiol. 2004 Oct;12(10):447-50. Review. No abstract available.


Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, van Kooyk Y, Geijtenbeek TB.

J Virol. 2004 Aug;78(15):8322-32.


Pathogens use carbohydrates to escape immunity induced by dendritic cells.

van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeek TB.

Curr Opin Immunol. 2004 Aug;16(4):488-93. Review.


Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect.

Wiens GD, Lekkerkerker A, Veltman I, Rittenberg MB.

J Immunol. 2001 Aug 15;167(4):2179-86.


Distinct functional domains in the cowpea mosaic virus movement protein.

Lekkerkerker A, Wellink J, Yuan P, van Lent J, Goldbach R, van Kammen AB.

J Virol. 1996 Aug;70(8):5658-61.

Supplemental Content

Loading ...
Support Center